Patent details

EP1944371 Title: Neisseria meningitidis antigens and compositions.

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
EP1944371
WO Application Number:
Type:
European Patent Granted for NL
Status:
Lapsed by non-payment of annual fee Art. 62 ROW
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP08003373.1
WO Publication Number:
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
Switzerland (CH)
Publications:

Dates

Filing date:
30/04/1999
Grant date:
04/03/2015
EP Publication Date:
04/03/2015
WO Publication Date:
Claims Translations Received Date:
Claims Translation B1 Received Date:
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
01/05/2018
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
04/03/2015
EP B1 Publication Date:
04/03/2015
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
10/04/2015
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
29/04/2019
Lapsed By Expiration Date:
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:

Applicant/holder

From:
17/11/2015
 
 

 

Name:
GlaxoSmithKline Biologicals S.A.
Address:
Rue de l'Institut 89, 1330, Rixensart, Belgium (BE)

Historical Applicant/holder

From:
17/11/2015
To:
17/11/2015

 

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056 BASEL, Switzerland (CH)

From:
17/11/2015
To:
17/11/2015

 

Name:
Novartis Vaccines and Diagnostics, Inc.
Address:
350 Massachusetts Avenue, CAMBRIDGE, MA 02139, United States of America (US)

From:
04/03/2015
To:
17/11/2015

 

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056 BASEL, Switzerland (CH)

From:
04/03/2015
To:
17/11/2015

 

Name:
J. Craig Venter Institute, Inc.
Address:
9704 Medical Center Drive, ROCKVILLE, MD 20850, United States of America (US)

Domicile Holder

Name:
ir. F.A. Geurts c.s.
From:
04/03/2015
Address:
Octrooibureau Vriesendorp & Gaade B.V. Koninginnegracht 19, 2514 AB, Den Haag, Netherlands (NL)
To:

Inventor

1

Name:
Fraser, Claire
Address:
ROCKVILLE, MD 20850, United States of America (US)

2

Name:
Galeotti, Cesira
Address:
53100 SIENA, Italy (IT)

3

Name:
Grandi, Guido
Address:
53100 SIENA, Italy (IT)

4

Name:
Hickey, Erin
Address:
ROCKVILLE, MD 20850, United States of America (US)

5

Name:
Masignani, Vega
Address:
53100 SIENA, Italy (IT)

6

Name:
Mora, Mariarosa
Address:
53100 SIENA, Italy (IT)

7

Name:
Petersen, Jeremy
Address:
ROCKVILLE, MD 20850, United States of America (US)

8

Name:
Pizza, Mariagratia
Address:
53100 SIENA, Italy (IT)

9

Name:
Rappuoli, Rino
Address:
53100 SIENA, Italy (IT)

10

Name:
Ratti, Giulio
Address:
53100 SIENA, Italy (IT)

11

Name:
Scalato, Enzo
Address:
53100 SIENA, Italy (IT)

12

Name:
Scarselli, Maria
Address:
53100 SIENA, Italy (IT)

13

Name:
Tettelin, Hervé
Address:
ROCKVILLE, MD 20850, United States of America (US)

14

Name:
Venter, J. Craig
Address:
ROCKVILLE, MD 20850, United States of America (US)

Priority

1

Priority Patent Number:
121528 P
Priority Date:
25/02/1999
Priority Country:
United States of America (US)

2

Priority Patent Number:
103796 P
Priority Date:
09/10/1998
Priority Country:
United States of America (US)

3

Priority Patent Number:
103794 P
Priority Date:
09/10/1998
Priority Country:
United States of America (US)

4

Priority Patent Number:
103749 P
Priority Date:
09/10/1998
Priority Country:
United States of America (US)

5

Priority Patent Number:
99062 P
Priority Date:
02/09/1998
Priority Country:
United States of America (US)

6

Priority Patent Number:
98994 P
Priority Date:
02/09/1998
Priority Country:
United States of America (US)

7

Priority Patent Number:
94869 P
Priority Date:
31/07/1998
Priority Country:
United States of America (US)

8

Priority Patent Number:
83758 P
Priority Date:
01/05/1998
Priority Country:
United States of America (US)

Classification

Main IPC Class:
C12N 15/31;
IPC or IDT classification:
A61K 39/095; C07K 14/22; C07K 16/12; C12Q 1/68; G01N 33/50;

Publication

Bulletin

1

Bulletin Heading:
VRV
Journal edition number:
50/18
Publication date:
05/12/2018
Description:
Lapse or annulment

2

Bulletin Heading:
CO
Journal edition number:
14/16
Publication date:
06/04/2016
Description:
Changes in the Netherlands Patent Register

3

Bulletin Heading:
CO
Journal edition number:
14/16
Publication date:
06/04/2016
Description:
Changes in the Netherlands Patent Register

4

Bulletin Heading:
EP3
Journal edition number:
2015/17
Publication date:
22/04/2015
Description:
European patents granted for the Netherlands in which a translation was filed ex Article 52 par. 1 of the NL Patent Law 1995

5

Bulletin Heading:
EP2
Journal edition number:
2015/11
Publication date:
11/03/2015
Description:
European patents granted for the Netherlands

European Patent Bulletin

Issue number:
201510
Publication date:
04/03/2015
Description:
Grant (B1)

Deed

Change of owner(s)

Change Kind/ Decision Type:
Assignment
Deed Number:
RC201600484A
Date Registered:
17/11/2015
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. F.A. Geurts c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

1

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056 BASEL, Switzerland (CH)

2

Name:
Novartis Vaccines and Diagnostics, Inc.
Address:
350 Massachusetts Avenue, CAMBRIDGE, MA 02139, United States of America (US)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Change of owner(s)

Change Kind/ Decision Type:
Assignment
Deed Number:
RC201600484B
Date Registered:
17/11/2015
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. F.A. Geurts c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

Name:
GlaxoSmithKline Biologicals S.A.
Address:
Rue de l'Institut 89, 1330, Rixensart, Belgium (BE)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Annual Fee

Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
18/04/2017
Last Annual Fee Paid Number:
19
Last Annual Fee Paid Amount:
1300 Euro
Payer:
Master Data Center
Filing date Document type Document Description Number of pages File Type
14/03/2016 Request for Change Subsequently filed deed 2 PDF /3/7/3/3/0/0508003373/docs/ep08003373.1_5_rfc20160330035619020.pdf
17/11/2015 Request for Change Accompanying letter deed 2 PDF /3/7/3/3/0/0508003373/docs/ep08003373.1_1_rfc20160330040006654.pdf
17/11/2015 Request for Change First filed deed 2 PDF /3/7/3/3/0/0508003373/docs/ep08003373.1_2_rfc20160330041423986.pdf
17/11/2015 Request for Change First filed deed 2 PDF /3/7/3/3/0/0508003373/docs/ep08003373.1_3_rfc20160330035815701.pdf
15/04/2015 Outgoing Correspondence Outgoing Letter 1 PDF /3/7/3/3/0/0508003373/docs/ep08003373.1_7_outgoingcorrespondence20150415.pdf
10/04/2015 Outgoing Correspondence Outgoing Letter 1 PDF /3/7/3/3/0/0508003373/docs/ep08003373.1_0_outgoingcorrespondence20150410.pdf
10/04/2015 Claims Translated claims 2 PDF /3/7/3/3/0/0508003373/docs/ep08003373.1_4_claims20150410.pdf
10/04/2015 Incoming Correspondence Paper Accompanying letter incoming document 2 PDF /3/7/3/3/0/0508003373/docs/ep08003373.1_6_incomingcorrespondencepaper20150410.pdf